Follistatin and Systolic Function at Follow-Up in STEMI Patients: A Cardiac Magnetic Resonance Study
Background/Objectives: Early circulating biomarkers capable of identifying patients at risk for impaired recovery of left ventricular (LV) systolic function after ST-segment elevation myocardial infarction (STEMI) remain limited. This exploratory study aims to determine whether serum follistatin measured within the first 24 h after coronary revascularization is associated with long-term LV systolic function, as assessed by cardiac magnetic resonance (CMR). Methods: In this prospective study, 31 patients with reperfused STEMI underwent serial CMR at 1 week and 6 months. Follistatin levels were measured within 24 h after revascularization. Associations between follistatin and CMR-derived LV systolic function were assessed using univariate and multivariable linear regression analyses. Results: Patients were stratified by median follistatin level (438 pg/mL) into below median (n = 15) and above median (n = 16). At 1 week, CMR-derived LV function, volumes, and structural indices were similar between groups. By 6 months, however, patients with follistatin above the median had higher LV ejection fraction (LVEF) [62 ± 9% vs. 54 ± 9%; p-value = 0.018] and lower LV end-systolic volume index (28 ± 12 vs. 41 ± 18 mL/m2; p-value = 0.037). In univariate analysis, follistatin was associated with 6-month LVEF (β = 0.027 per pg/mL; p-value = 0.004). After multivariable adjustment, follistatin remained independently associated with 6-month LVEF (β = 0.024 per pg/mL; p-value < 0.001) and with relative improvement in LVEF from 1 week to 6 months (β = 0.044 per pg/mL; p-value < 0.001). Conclusions: In reperfused STEMI patients, higher early follistatin levels were independently associated with more favorable LV systolic function at 6 months. These hypothesis-generating findings suggest that follistatin may represent a potential biomarker of subsequent systolic recovery after STEMI, warranting further validation in larger prospective studies.
Authors
- Elena de Dios (ORCID: https://orcid.org/0000-0002-9620-8839)
- H Merenciano-Gonzalez (ORCID: https://orcid.org/0000-0002-1734-0381)
- Nerea Pérez-Solé (ORCID: https://orcid.org/0000-0003-3527-0337)
- Tamara Molina-García (ORCID: https://orcid.org/0009-0006-0737-500X)
- Vicente Bodı́ (ORCID: https://orcid.org/0000-0001-6425-5828)
- Antoni Bayés‐Genís (ORCID: https://orcid.org/0000-0002-3044-197X)
- José Gavara (ORCID: https://orcid.org/0000-0002-3483-7066)
- Julio E. Núñez (ORCID: https://orcid.org/0000-0003-1672-7119)
- César Ríos‐Navarro (ORCID: https://orcid.org/0000-0002-6405-6279)
- Víctor Marcos‐Garcés (ORCID: https://orcid.org/0000-0001-5565-5547)
- A Ruiz-Sauri
Institutions
- Universitat de València (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-07-23
- DOI
- https://doi.org/10.3390/jcm15155777
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00